This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0883073808319070v1 23/12/1392    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Jerrell, J. M. Articles by Livingston, T. S. Search for Related Content PubMed PubMed Citation Articles by Jerrell, J. M. Articles by Livingston, T. S. Pubmed/NCBI databases Medline Plus Health Information Neurologic Diseases Social Bookmarking                         What's this?

Neurological Adverse Events Associated With Antipsychotic Treatment in Children and Adolescents

From the Departments of Neuropsychiatry and Pediatrics, University of South Carolina School of Medicine, Columbia, SC

^* To whom correspondence should be addressed. E-mail: jjerrell{at}gw.mp.sc.edu.

	Abstract

A retrospective cohort design using medical and pharmacy claims from one state’s Medicaid program compared incidence rates for neurological adverse events associated with antipsychotic use in 4140 youths prescribed antipsychotic medications and an untreated sample of 4500 youths, January 1998 to December 2005. The treated cohort evinced a higher prevalence of involuntary movements, sedation, and seizures. The odds of incident involuntary movements were significantly higher for those taking aripiprazole, risperidone, haloperidol, and multiple antipsychotics. The odds of incident seizures were greater for those taking risperidone, multiple antipsychotics, and serotonin-specific reuptake inhibitors. The odds of incident sedation were greater for those taking ziprasidone, risperidone, quetiapine, multiple antipsychotics, and serotonin-specific reuptake inhibitors. Exposure to risperidone, multiple antipsychotics, and serotonin-specific reuptake inhibitors consistently confers a higher risk of developing a range of neurological adverse events in young patients, especially those with preexisting central nervous system, mental retardation, or cardiovascular disorders.

First published on September 4, 2008, doi:10.1177/0883073808319070

Journal of Child Neurology 2008;23:1392.

A more recent version of this article appeared on December 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?